my fasting insulin moved and I cannot work out whether Zepbound is why
Posting this as a discussion rather than a claim: my fasting insulin moved and I cannot work out whether Zepbound is why.
Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.
The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to.
SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.
Would rather be corrected in public than confident in private.
best — the order this archive was captured in
The step schedule question, answered properly, because it comes up weekly.
The label sets a minimum interval of four weeks between increases. That is a floor on how fast you may go, and it exists because tolerability, not efficacy, is what limits most people. There is nothing in the pharmacology that says you must increase at four weeks, or at eight, or ever.
What decides it in practice is whether the effect you want is still there. If appetite is quiet and the trend is going the right way, the dose is doing its job. If both have genuinely gone flat for six weeks or more, that is a conversation worth having with someone who knows your history.
That percentage is body weight change, not body fat. Different measurement, and the distinction gets lost every time.
a lot of people plateau nicely at 10mg and never need 15
zepbound and mounjaro are the same compound with different labels
Disagree with the conversion table. There is no validated equivalence between the two molecules and posting one as though there is does real damage.
2.5mg is a four-week starting dose, not a maintenance dose. Worth being precise since people search these threads.
2.5mg is a four-week starting dose, not a maintenance dose.
Agreed, with one qualifier: that is the mean of the top arm and the spread around it was enormous.
It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.
Does fatigue follow the day after the shot, or is it spread across the week?
the four-week step schedule is the label, not folklore
Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.
Pen or vial? The step sizes available differ and it changes this answer.
week 9 is early to draw any conclusion at all
Correction to my own post above — I said 12.5mg and I have been on 5mg since the spring. Same argument, wrong number.
Switching from semaglutide, since three people asked in this thread alone.
There is no published dose equivalence between the two. The conversion tables that circulate are somebody’s arithmetic, not data. What people report here is that the first month after a switch is often flat, that the appetite effect feels differently shaped rather than simply stronger, and that starting at the bottom of the ladder again is the common approach.
None of that is a recommendation. It is what the threads say, and the threads are not a clinic.
Push back: "gentler than sema" is a population statement. Plenty of people on this board have the opposite experience and they are not doing it wrong.
The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.
Not sure that follows. You went up a step and changed your training in the same fortnight.
On comparing yourself with the trial number.
SURMOUNT-1 reported roughly 21% mean body weight change at 72 weeks on the highest arm. Three things get dropped every time that figure is quoted here. It is a mean, and the distribution around it is very wide. It is 72 weeks, which is a year and a half. And it is a trial population with trial support, which is not the same as a person with a spreadsheet.
Use it as a rough shape, not a benchmark. A 12% year is inside the ordinary range and people quit over it every week on this board.
Sulphur burps for the first eight days after each step, then nothing. Predictable enough that I planned my week around it.
Sulphur burps for the first eight days after each step, then nothing.
Saving this one. It is the clearest statement of the stall problem I have read here.
dual agonist, so the GIP arm is doing something the sema threads will not tell you about
Left up, flair changed to Discussion. It is an opinion post and that is fine as long as it is labelled.
[deleted]
the trials titrated on a calendar, real people titrate on symptoms
stepping every four weeks is a ceiling on speed, not a schedule you must hit
SURMOUNT-1 landed around 21% at 72 weeks on the top arm
What is the waist doing? That is usually the number still moving during a scale stall.
sulphur burps are the signature complaint and they are not dangerous
switching from sema is not a dose conversion, there is no clean equivalence
- 1It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part…7 comments in this branch · started by u/incretin_ivy